Advertisement
U.S. markets close in 31 minutes

BrainsWay Ltd. (BWAY)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
6.320.00 (0.00%)
As of 03:12PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close6.32
Open6.37
Bid6.29 x 1000
Ask6.35 x 1100
Day's Range6.12 - 6.67
52 Week Range1.38 - 7.61
Volume84,159
Avg. Volume185,868
Market Cap106.602M
Beta (5Y Monthly)0.35
PE Ratio (TTM)N/A
EPS (TTM)-0.48
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for BWAY

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Brainsway Ltd.
    Analyst Report: Silk Road Medical IncBased in Sunnyvale, California, Silk Road Medical is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR combines the surgical principles of neuroprotection with minimally invasive endovascular techniques to treat carotid artery blockages that may cause strokes. The TCAR procedure involves threading a balloon catheter into the carotid artery from an incision near the groin to expand the narrowed artery. In parallel with the catheter procedure, another device is deployed to temporarily reverse blood flow to the brain in the treated artery in order to prevent any broken off clots from moving to the brain.
    Rating
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • GlobeNewswire

    BrainsWay to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024

    BURLINGTON, Mass. and JERUSALEM, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its fourth quarter and full year 2023 financial results as well as operational highlights before the open of the U.S. financial markets on Wednesday, March 6, 2024. The Company will host a conference call and webcast at 8:30 AM Eas

  • InvestorPlace

    7 High-Growth Stocks to Snag for Spectacular Returns in 2024

    In the stock market, pursuing high-growth stocks becomes a compelling venture, akin to searching for pearls in the vast sea of possibilities. The year 2024 unfolds with promises of prosperity and strategic opportunities, and within this realm, seven stocks emerge as yielders of potential riches. Picture a dynamic space where each stock is a thread contributing to the grand design of wealth creation. With its remarkable surge in total revenue and efficient scalability, the first one sets the stag

  • InvestorPlace

    Biotech Stocks Are on Fire: Here Are the Top 3 Picks for January

    From CRISPR gene editing to modify ideal agricultural traits, synthetic biology to promote eco-friendly engineering, or even that relating to biofuels, the field of biotechnology, also known as biotech, offers exciting disruptive solutions with the potential to expand to market caps worth trillions! With new catalysts such as artificial intelligence and quantum computing offering methods to unlock complicated data sets to hasten drug development pipelines, it’s no wonder that this market has a p